Ergomed plc Board Changes (9974X)
May 10 2021 - 1:00AM
UK Regulatory
TIDMERGO
RNS Number : 9974X
Ergomed plc
10 May 2021
PRESS RELEASE
Mark Enyedy Appointed to Board as Non-Executive Director
Guildford, UK - 10 May 2021: Ergomed plc (LSE: ERGO) ("Ergomed"
or the "Company"), a company focused on providing specialised
services to the pharmaceutical industry, today announces that Mark
Enyedy will join the Board as a Non-Executive Director with effect
from 10 June 2021.
Mr Enyedy brings more than 25 years of senior leadership
experience in the biopharmaceutical sector, including executive
management, corporate development and legal roles, across multiple
therapeutic areas with a focus on rare diseases and oncology. He is
currently President and Chief Executive Officer and a Director of
ImmunoGen, Inc., a publicly-traded biotechnology company, where he
oversees strategy and operations. He is also a member of the Board
of Directors of the Biotechnology Innovation Organization (BIO),
the world's largest advocacy organisation representing the
biotechnology industry in the US and globally.
Prior to ImmunoGen, Mr Enyedy served in various executive
capacities at Shire plc, including as Executive Vice President and
Head of Corporate Development, a role in which he negotiated and
integrated the multi-billion dollar acquisitions of NPS
Pharmaceuticals and Dyax Corp. and oversaw the $32 billion
combination with Baxalta, Inc. Mr Enyedy was also previously
President of the Transplant, Oncology and Multiple Sclerosis
division at Genzyme Corporation, and under his leadership the
division achieved revenue growth from under $10 million to more
than $675 million in just seven years. He began his career as an
attorney at Palmer & Dodge, a Boston-based law firm where his
practice focused on representing biopharmaceutical, high
technology, and energy companies in M&A, licensing, and
financing transactions.
Mr Enyedy also serves on the Boards of Directors of The American
Cancer Society of Eastern New England and LogicBio Therapeutics,
Inc. (Nasdaq: LOGC). He holds a J.D. from Harvard Law School and a
B.S. from Northeastern University.
Dr Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Mark has extensive corporate development experience in
the US, UK and globally from his time in senior public company
strategic leadership roles. Throughout his career he has achieved
an outstanding and consistent track record of building new
businesses through organic growth, corporate development, and
M&A. Over the past 20 years, he has been strongly focused on
rare disease and oncology, and brings to Ergomed exceptional levels
of expertise, insight and connections which will support our
continuing drive to strengthen our global leadership in these
sectors. Mark is an outstanding addition to Ergomed, and on behalf
of the Board, I am delighted to warmly welcome him to his new
position."
Mark Enyedy said: "Ergomed is at an exciting stage in its
development. The Company's success in recent years reflects the
continued strong execution of both its organic and inorganic growth
strategy, creating leadership positions in its chosen high-growth
specialist markets. I look forward to working closely with the
management team to develop innovative strategies that will
accelerate the company's continued international growth."
Mr Mark Joseph Enyedy, aged 57, holds or has held directorships
in the five years preceding his appointment at Ergomed as
follows:
Current Directorships: Akebia Therapeutics Inc
Immunogen BioPharma (Ireland) Limited
Immunogen Europe Limited
Immunogen Inc
Immunogen Securities Corp
LogicBio Therapeutics Inc
The American Cancer Society of
Eastern New England
The Biotechnology Innovation Organization
Directorships in the past five Fate Therapeutics Inc
years: Immunogen (Bermuda) Ltd
Keryx Biopharmaceuticals, Inc.
-------------------------------------------
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive
Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Freddie Barnfield / Matthew O'Dowd
(Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709
- for UK enquiries 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray / Olivia Manser
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand, a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO), and an internationally recognised specialist expertise in
orphan drug development, under PSR. For further information, visit:
http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFLFSSESIAIIL
(END) Dow Jones Newswires
May 10, 2021 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2023 to Apr 2024